PDF(Pubmed)
Abstract：
Extensive-stage small-cell lung cancer (ES-SCLC) is highly malignant, with early metastasis and high recurrence. Since therapeutic options are limited, ES-SCLC has a characteristically short survival period and extremely poor prognosis. A combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs can achieve promising efficacy and safety in patients with ES-SCLC as a second-line or subsequent treatment, extending survival to some extent. However, the clinical outcomes remain mostly unsatisfactory and are sometimes affected by treatment-related adverse events.
A 57-year-old woman with ES-SCLC was administered a combination therapy of atezolizumab (a PD-L1 inhibitor) and anlotinib [an oral multi-targeted tyrosine kinase inhibitor (TKI)]. She survived for 22 months, with no disease progression during the 28 courses of therapy. Unexpectedly, despite having no history of asthma, the patient developed asthma while receiving this regimen. This is possibly related to T-cell activation and the tumor immune microenvironment, which induce allergic inflammation after PD-L1 blockade.
This is the first report of an asthma-negative ES-SCLC patient who developed asthma after receiving atezolizumab plus anlotinib. Although this combination therapy may effectively extend survival in SCLC patients, asthmatic symptoms should be closely monitored.
A 57-year-old woman with ES-SCLC was administered a combination therapy of atezolizumab (a PD-L1 inhibitor) and anlotinib [an oral multi-targeted tyrosine kinase inhibitor (TKI)]. She survived for 22 months, with no disease progression during the 28 courses of therapy. Unexpectedly, despite having no history of asthma, the patient developed asthma while receiving this regimen. This is possibly related to T-cell activation and the tumor immune microenvironment, which induce allergic inflammation after PD-L1 blockade.
This is the first report of an asthma-negative ES-SCLC patient who developed asthma after receiving atezolizumab plus anlotinib. Although this combination therapy may effectively extend survival in SCLC patients, asthmatic symptoms should be closely monitored.
摘要：
■广泛期小细胞肺癌（ES-SCLC）是高度恶性的，早期转移和高复发。由于治疗选择有限，ES-SCLC的特点是生存期短，预后极差。免疫检查点抑制剂（ICIs）和抗血管生成药物的组合可以在ES-SCLC患者中作为二线或后续治疗获得有希望的疗效和安全性，在一定程度上延长生存时间。然而,临床结局大多不令人满意,有时会受到治疗相关不良事件的影响.
■一名患有ES-SCLC的57岁女性患者接受了阿特珠单抗（PD-L1抑制剂）和安洛替尼[一种口服多靶向酪氨酸激酶抑制剂（TKI）]的联合治疗。她活了22个月,在28个疗程的治疗过程中没有疾病进展。出乎意料的是,尽管没有哮喘病史,患者在接受该方案时出现哮喘.这可能与T细胞活化和肿瘤免疫微环境有关,在PD-L1阻断后诱导过敏性炎症。
■这是首例哮喘阴性ES-SCLC患者在接受阿特珠单抗联合安洛替尼后发展为哮喘的报告。虽然这种联合治疗可以有效延长SCLC患者的生存期，应密切监测哮喘症状。
■一名患有ES-SCLC的57岁女性患者接受了阿特珠单抗（PD-L1抑制剂）和安洛替尼[一种口服多靶向酪氨酸激酶抑制剂（TKI）]的联合治疗。她活了22个月,在28个疗程的治疗过程中没有疾病进展。出乎意料的是,尽管没有哮喘病史,患者在接受该方案时出现哮喘.这可能与T细胞活化和肿瘤免疫微环境有关,在PD-L1阻断后诱导过敏性炎症。
■这是首例哮喘阴性ES-SCLC患者在接受阿特珠单抗联合安洛替尼后发展为哮喘的报告。虽然这种联合治疗可以有效延长SCLC患者的生存期，应密切监测哮喘症状。
